GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » Sloan Ratio %

WXXWY (WuXi Biologics (Cayman)) Sloan Ratio % : 2.58% (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

WuXi Biologics (Cayman)'s Sloan Ratio for the quarter that ended in Jun. 2024 was 2.58%.

As of Jun. 2024, WuXi Biologics (Cayman) has a Sloan Ratio of 2.58%, indicating the company is in the safe zone and there is no funny business with accruals.


WuXi Biologics (Cayman) Sloan Ratio % Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Sloan Ratio % Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.43 24.25 21.71 9.66 3.46

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.96 9.94 4.77 3.46 2.58

Competitive Comparison of WuXi Biologics (Cayman)'s Sloan Ratio %

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Sloan Ratio % falls into.



WuXi Biologics (Cayman) Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

WuXi Biologics (Cayman)'s Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(476.139-653.723
--452.125)/7923.549
=3.46%

WuXi Biologics (Cayman)'s Sloan Ratio for the quarter that ended in Jun. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jun. 2024 )
=(365.323-448.054
--282.288)/7733.706
=2.58%

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. WuXi Biologics (Cayman)'s Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was 158.687 (Dec. 2023 ) + 206.636 (Jun. 2024 ) = $365 Mil.
WuXi Biologics (Cayman)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 was 268.568 (Dec. 2023 ) + 179.486 (Jun. 2024 ) = $448 Mil.
WuXi Biologics (Cayman)'s Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2024 was -229.56 (Dec. 2023 ) + -52.728 (Jun. 2024 ) = $-282 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (OTCPK:WXXWY) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2024, WuXi Biologics (Cayman) has a Sloan Ratio of 2.58%, indicating the company is in the safe zone and there is no funny business with accruals.


WuXi Biologics (Cayman) Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) Business Description

Traded in Other Exchanges
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.